Previous 10 | Next 10 |
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...
2024-01-05 12:32:13 ET DENVER, Colo., Jan. 5, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Banzai International Inc (NASDAQ: BNZI), Dermata Therapeutics (NASDAQ: DRMA), Ainos Inc (NASDAQ: AIMD),...
2024-01-05 10:07:14 ET DENVER, Colo., Jan. 5, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Banzai International Inc (NASDAQ: BNZI), Immunic Inc (NASDAQ: IMUX), Dermata Therapeutics (NASDAQ: DRMA), Aino...
2024-01-05 09:06:45 ET More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics For further details see: Dermata stock soars o...
2024-01-04 16:51:37 ET DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced, after today’s market close, that it was issued a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis, entitled “Comp...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Der...
2023-12-18 14:46:47 ET Top 3 Strategies to Use for Trading Penny Stocks Next Year Penny stocks are a popular but risky investment option due to their potential for high returns. Having a trading strategy with penny stocks is important in order to minimize the risk involved and maximize ...
2023-12-08 08:07:30 ET More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics For further details see: Dermata Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...